Actively Recruiting

Phase 3
Age: 18Years - 69Years
All Genders
NCT05974462

MYTHS-MR Trial (MYocarditis THerapy With Steroids in Patients With Mildly Reduced Ejection Fraction)

Led by University Hospital, Antwerp · Updated on 2025-04-17

174

Participants Needed

19

Research Sites

227 weeks

Total Duration

On this page

Sponsors

U

University Hospital, Antwerp

Lead Sponsor

N

Niguarda Hospital

Collaborating Sponsor

AI-Summary

What this Trial Is About

The goal of this clinical trial is to demonstrate the efficacy of pulsed intravenous methylprednisolone in a single-blind randomized controlled trial versus standard therapy in patients with acute myocarditis and a mildly reduced LVEF. The main question\[s\] it aims to answer are: * is there an increase in LVEF (≥55% or an absolute increase in LVEF ≥ 10%) on echocardiogram after 5 days from randomization in patients treated with pulsed corticosteroid therapy vs. standard therapy? * is there a reduction in the proportion of patients with LVEF \< 55% AND/OR LV dilation on a 6-month CMRI in patients treated pulsed corticosteroid therapy vs. standard therapy? * To assess the effect of corticosteroids on the occurrence of the combined endpoint(1) all-cause death or (2) HTx or (3) long-term LVAD implant or (4) first rehospitalization due to HF or ventricular arrhythmias, or advanced AV block. Participants will be randomized in two arms in a 1:1 ratio. The experimental group will receive pulsed corticosteroid therapy on top of the standard therapy and patients in the placebo group will be treated with a saline solution on top of their standard therapy. All other tests are executed according to standard of care.

CONDITIONS

Official Title

MYTHS-MR Trial (MYocarditis THerapy With Steroids in Patients With Mildly Reduced Ejection Fraction)

Who Can Participate

Age: 18Years - 69Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Left ventricular ejection fraction (LVEF) below 50% and left ventricular end-diastolic diameter (LV-EDD) less than 56 mm on echocardiogram
  • Increased troponin levels (3 times the upper reference limit) at randomization
  • Cardiac symptoms started within 3 weeks before randomization
  • Coronary artery disease excluded by angiogram in patients aged 46 or older if myocarditis is not confirmed by biopsy
  • Randomization within 120 hours of hospital admission
  • Endomyocardial biopsy optional based on local team decision
Not Eligible

You will not qualify if you...

  • Known systemic autoimmune disorder where immunosuppression is useful, except if diagnosed during hospitalization
  • Current chronic oral or intravenous corticosteroid or other immunosuppressive therapy (excluding colchicine or NSAIDs)
  • Allergy or contraindication to corticosteroids
  • Persistent peripheral eosinophilia over 7% or known hypereosinophilic syndrome
  • Myocarditis linked to immune checkpoint inhibitor therapy
  • Previously known chronic cardiac disease except recovered myocarditis
  • Active bacterial or fungal infection or suspected infection with high procalcitonin
  • Known chronic infections such as HIV or tuberculosis
  • Out-of-hospital cardiac arrest
  • Echocardiogram signs of other cardiac diseases like endocarditis
  • Participation in another clinical trial
  • Pregnant women or positive pregnancy test in women aged 18-50
  • Any serious disease with life expectancy less than 12 months or judged by investigator to interfere with trial
  • If LVEF under 41%, NT-proBNP must be below 1600 pg/mL or BNP below 400 pg/mL; no NT-proBNP or BNP limits if LVEF 41%-<50%

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 19 locations

1

Antwerp University Hospital

Edegem, Antwerp, Belgium

Actively Recruiting

2

Onze-Lieve-Vrouwziekenhuis (OLV ziekenhuis)

Aalst, Belgium

Actively Recruiting

3

Middelheim Ziekenhuis

Antwerp, Belgium

Actively Recruiting

4

Jessa ziekenhuis

Hasselt, Belgium

Actively Recruiting

5

Universitair ziekenhuis Leuven

Leuven, Belgium

Actively Recruiting

6

Niguarda Hospital

Milan, Milan, Italy, 20125

Actively Recruiting

7

Azienda USL Toscane SUD Est

Arezzo, Italy

Not Yet Recruiting

8

Azienda Ospedaliera Papa Giovanni XXIII

Bergamo, Italy

Not Yet Recruiting

9

ASST Spedali Civili di Brescia

Brescia, Italy, 25123

Not Yet Recruiting

10

Careggi University Hospital

Florence, Italy

Not Yet Recruiting

11

Alessandro Manzoni hospital

Lecco, Italy, 23900

Not Yet Recruiting

12

San Raffaele Hospital

Milan, Italy, 20132

Not Yet Recruiting

13

Ospedale Maggiore di Milano

Milan, Italy

Not Yet Recruiting

14

Fondazione IRCCS Policlinico San Matteo

Pavia, Italy

Not Yet Recruiting

15

Fondazione Toscana Gabriele Monasterio

Pisa, Italy

Not Yet Recruiting

16

Policlinico Universitario Agostino Gemelli

Roma, Italy

Not Yet Recruiting

17

Azienda Sanitaria Universitaria Friuli Centrale

Udine, Italy

Not Yet Recruiting

18

University Medical Centre of Ljubljana

Ljubljana, Slovenia

Actively Recruiting

19

Hospital Universitario A Coruña (CHUAC)

A Coruña, Spain, 15006

Not Yet Recruiting

Loading map...

Research Team

C

Caroline Van De Heyning, MD PhD

CONTACT

N

Nicole Sturkenboom, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here